Who
Lorena Raquel Lerner
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Keros Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $200K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Feb 2026
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K3,568 at $10.29 | filing |
| 18 Aug 2026filed 20 Aug 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K3,568 at $10.29 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K3,873 at $16.35 | filing |
| 18 Feb 2026filed 20 Feb 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K3,873 at $16.35 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)KROS · tickerreport.com · 24 Oct 2026Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)KROS · themarketsdaily.com · 24 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Lorena Raquel Lerner; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.